November 9, 2020

What Pfizer’s landmark COVID vaccine results mean for the pandemic

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): vaccines

[Press release, not peer-reviewed] Pfizer and BioNTech announced that the BNT162b2 mRNA vaccine had 90% efficacy in preventing COVID-19 in an interim analysis of an ongoing Phase 3 trial. This is the first SARS-CoV-2 vaccine trial to release Phase 3 efficacy data. The trial includes 43,538 participants, 94 of whom developed COVID-19. The press release did not indicate the number of cases accrued in the vaccine versus placebo groups. No serious adverse events have been reported for this two-dose vaccine. A Nature news article also covered the announcement.

Press release downloaded Nov. 9 from https://www.businesswire.com/news/home/20201109005539/en/

Callaway. (Nov 9, 2020). What Pfizer’s landmark COVID vaccine results mean for the pandemic. Nature. https://doi.org/10.1038/d41586-020-03166-8